Research programme: anti-CXCR4 monoclonal antibodies - Northwest Biotherapeutics
Alternative Names: Antibodies to CXCR4 - Northwest BiotherapeuticsLatest Information Update: 04 Nov 2017
At a glance
- Originator Northwest Biotherapeutics
- Class Monoclonal antibodies
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Aug 2010 Preclinical development is ongoing in USA
- 19 Feb 2008 Research programme is still in preclinical trials for Cancer in USA